{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:42:59Z","timestamp":1782996179859,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroscience Methods"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jneumeth.2022.109551","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T02:06:29Z","timestamp":1646186789000},"page":"109551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["A bioassay for neuromuscular junction-restricted complement activation by myasthenia gravis acetylcholine receptor antibodies"],"prefix":"10.1016","volume":"373","author":[{"given":"Jaap J.","family":"Plomp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje G.M.","family":"Huijbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.G.M.","family":"Verschuuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Borodovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneumeth.2022.109551_bib1","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420935697","article-title":"C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis","volume":"13","author":"Aguirre","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jneumeth.2022.109551_bib2","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3389\/fimmu.2020.00917","article-title":"Complement inhibitor therapy for myasthenia gravis","volume":"11","author":"Albazli","year":"2020","journal-title":"Front Immunol."},{"issue":"8","key":"10.1016\/j.jneumeth.2022.109551_bib3","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1021\/bi00511a017","article-title":"Monoclonal antibodies as probes of acetylcholine receptor structure. 2. Binding to native receptor","volume":"20","author":"Conti-Tronconi","year":"1981","journal-title":"Biochemistry"},{"issue":"11","key":"10.1016\/j.jneumeth.2022.109551_bib4","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41582-020-0400-0","article-title":"Complement in neurological disorders and emerging complement-targeted therapeutics","volume":"16","author":"Dalakas","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"6176","key":"10.1016\/j.jneumeth.2022.109551_bib5","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.1248943","article-title":"Complement is activated by IgG hexamers assembled at the cell surface","volume":"343","author":"Diebolder","year":"2014","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.jneumeth.2022.109551_bib6","first-page":"267","article-title":"Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations","volume":"52","author":"Engel","year":"1977","journal-title":"Mayo Clin. Proc."},{"issue":"2","key":"10.1016\/j.jneumeth.2022.109551_bib7","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1124\/pharmrev.120.000072","article-title":"Therapeutic targeting of the complement system: from rare diseases to pandemics","volume":"73","author":"Garred","year":"2021","journal-title":"Pharm. Rev."},{"issue":"1","key":"10.1016\/j.jneumeth.2022.109551_bib8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"10","key":"10.1016\/j.jneumeth.2022.109551_bib9","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1172\/JCI30383","article-title":"Calpain activation impairs neuromuscular transmission in a mouse model of the slow-channel myasthenic syndrome","volume":"117","author":"Groshong","year":"2007","journal-title":"J. Clin. Invest"},{"issue":"1","key":"10.1016\/j.jneumeth.2022.109551_bib10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: the role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann. N. Y Acad. Sci."},{"issue":"5","key":"10.1016\/j.jneumeth.2022.109551_bib11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/13543784.2021.1897567","article-title":"Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis","volume":"30","author":"Howard","year":"2021","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"8","key":"10.1016\/j.jneumeth.2022.109551_bib12","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archneurol.2012.437","article-title":"Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis","volume":"69","author":"Jacob","year":"2012","journal-title":"Arch. Neurol."},{"issue":"3","key":"10.1016\/j.jneumeth.2022.109551_bib13","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/cyto.b.20454","article-title":"A rapid, fluorescence-based assay for detecting antigenic modulation of the acetylcholine receptor on human cell lines","volume":"76","author":"Keefe","year":"2009","journal-title":"Cytom. B Clin. Cytom."},{"issue":"Pt 4","key":"10.1016\/j.jneumeth.2022.109551_bib14","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/brain\/aws025","article-title":"Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice","volume":"135","author":"Klooster","year":"2012","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.jneumeth.2022.109551_bib15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/mus.23448","article-title":"Cell surface complement regulators moderate experimental myasthenia gravis pathology","volume":"47","author":"Kusner","year":"2013","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jneumeth.2022.109551_bib16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/1744666X.4.1.43","article-title":"Effect of complement and its regulation on myasthenia gravis pathogenesis","volume":"4","author":"Kusner","year":"2008","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.jneumeth.2022.109551_bib17","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/nyas.13555","article-title":"Acetylcholine receptor antibody-mediated animal models of myasthenia gravis and the role of complement","volume":"1413","author":"Kusner","year":"2018","journal-title":"Ann. N. Y Acad. Sci."},{"issue":"1\u20132","key":"10.1016\/j.jneumeth.2022.109551_bib18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jim.2009.11.003","article-title":"Preparing serum for functional complement assays","volume":"352","author":"Lachmann","year":"2010","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jneumeth.2022.109551_bib19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.jneumeth.2022.109551_bib20","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1309\/AJCPYEOR6SGE8ZLU","article-title":"Detection of acetylcholine receptor modulating antibodies by flow cytometry","volume":"143","author":"Lozier","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.jneumeth.2022.109551_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cei.13411","article-title":"Carbamylation reduces the capacity of IgG for hexamerization and complement activation","volume":"200","author":"Lubbers","year":"2020","journal-title":"Clin. Exp. Immunol."},{"issue":"5","key":"10.1016\/j.jneumeth.2022.109551_bib22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/(SICI)1098-2825(1998)12:5<315::AID-JCLA12>3.0.CO;2-Y","article-title":"Development of an assay for modulating anti-acetylcholine receptor autoantibodies using human rhabdomyosarcoma cell line","volume":"12","author":"Lyons","year":"1998","journal-title":"J. Clin. Lab Anal."},{"key":"10.1016\/j.jneumeth.2022.109551_bib23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2147\/ITT.S261414","article-title":"Complement inhibition for the treatment of myasthenia gravis","volume":"9","author":"Mantegazza","year":"2020","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.jneumeth.2022.109551_bib24","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.semcdb.2017.06.009","article-title":"Molecular cell biology of complement membrane attack","volume":"72","author":"Morgan","year":"2017","journal-title":"Semin Cell Dev. Biol."},{"issue":"2","key":"10.1016\/j.jneumeth.2022.109551_bib25","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2249.2006.03205.x","article-title":"The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice","volume":"146","author":"Morgan","year":"2006","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.jneumeth.2022.109551_bib26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.jneumeth.2022.109551_bib27","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneumeth.2022.109551_bib28","first-page":"6","article-title":"Structural insights into the molecular mechanisms of myasthenia gravis and their therapeutic implications","author":"Noridomi","year":"2017","journal-title":"Elife"},{"issue":"2","key":"10.1016\/j.jneumeth.2022.109551_bib29","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/1531-8249(199902)45:2<189::AID-ANA9>3.0.CO;2-T","article-title":"Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates","volume":"45","author":"Plomp","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneumeth.2022.109551_bib30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.expneurol.2015.01.007","article-title":"Electrophysiological analysis of neuromuscular synaptic function in myasthenia gravis patients and animal models","volume":"270","author":"Plomp","year":"2015","journal-title":"Exp. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.jneumeth.2022.109551_bib31","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jneuroim.2004.08.002","article-title":"The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo","volume":"158","author":"Romi","year":"2005","journal-title":"J. Neuroimmunol."},{"issue":"3","key":"10.1016\/j.jneumeth.2022.109551_bib32","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ana.410430315","article-title":"End-plate voltage-gated sodium channels are lost in clinical and experimental myasthenia gravis","volume":"43","author":"Ruff","year":"1998","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.jneumeth.2022.109551_bib33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ncl.2018.01.001","article-title":"Nature and action of antibodies in myasthenia gravis","volume":"36","author":"Ruff","year":"2018","journal-title":"Neurol. Clin."},{"issue":"2","key":"10.1016\/j.jneumeth.2022.109551_bib34","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00005072-197803000-00008","article-title":"Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis","volume":"37","author":"Sahashi","year":"1978","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"1","key":"10.1016\/j.jneumeth.2022.109551_bib35","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4049\/jimmunol.154.1.180","article-title":"Multiple defects in innate and adaptive immunologic function in NOD\/LtSz-scid mice","volume":"154","author":"Shultz","year":"1995","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.jneumeth.2022.109551_bib36","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1073\/pnas.79.1.188","article-title":"Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies","volume":"79","author":"Tzartos","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jneumeth.2022.109551_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.612402","article-title":"Monoclonal antibodies capable of inhibiting complement downstream of C5 in multiple species","volume":"11","author":"Zelek","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.jneumeth.2022.109551_bib38","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.molimm.2019.07.030","article-title":"Compendium of current complement therapeutics","volume":"114","author":"Zelek","year":"2019","journal-title":"Mol. Immunol."},{"issue":"43","key":"10.1016\/j.jneumeth.2022.109551_bib39","doi-asserted-by":"crossref","first-page":"15269","DOI":"10.1523\/JNEUROSCI.3766-11.2011","article-title":"Skeletal muscle IP3R1 receptors amplify physiological and pathological synaptic calcium signals","volume":"31","author":"Zhu","year":"2011","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.jneumeth.2022.109551_bib40","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/hmg\/ddt397","article-title":"Selective inhibition of caspases in skeletal muscle reverses the apoptotic synaptic degeneration in slow-channel myasthenic syndrome","volume":"23","author":"Zhu","year":"2014","journal-title":"Hum. Mol. Genet"}],"container-title":["Journal of Neuroscience Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165027022000784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165027022000784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T01:00:50Z","timestamp":1759021250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165027022000784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":40,"alternative-id":["S0165027022000784"],"URL":"https:\/\/doi.org\/10.1016\/j.jneumeth.2022.109551","relation":{},"ISSN":["0165-0270"],"issn-type":[{"value":"0165-0270","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A bioassay for neuromuscular junction-restricted complement activation by myasthenia gravis acetylcholine receptor antibodies","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroscience Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneumeth.2022.109551","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109551"}}